Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT02947685. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer.
Study identification
- NCT ID
- NCT02947685
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 518 participants
Conditions and interventions
Interventions
- palbociclib Drug
- trastuzumab Drug
- pertuzumab Drug
- letrozole Drug
- Anastrozole Drug
- Exemestane Drug
- Fulvestrant Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 21, 2017 (Actual)
- Primary completion
- Oct 15, 2024 (Actual)
- Completion
- Jul 31, 2026 (Estimated)
- Last update posted
- Feb 12, 2026
2017 – 2026
United States locations
- U.S. sites
- 35
- U.S. states
- 24
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSF | San Francisco | California | 94115 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Baycare Healthcare (Morton Plant Mease) | Clearwater | Florida | 33756 | — |
| Memorial Healthcare System | Hollywood | Florida | 33021 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Florida Hospital | Orlando | Florida | 32804 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| University of Illinois at Chicago | Chicago | Illinois | 60612 | — |
| Ingalls Memorial Hospital | Harvey | Illinois | 60426 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67214 | — |
| Ochsner Medical Center Jefferson | New Orleans | Louisiana | 70121 | — |
| New England Cancer Specialists | Scarborough | Maine | 04074 | — |
| University of Maryland - Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | — |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | Maryland | 21287 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Lowell General Hospital | Lowell | Massachusetts | 01854 | — |
| Michigan Cancer Research Consortium (St. Joseph Mercy Hospital | Ann Arbor | Michigan | 48106 | — |
| West Michigan Cancer Center | Grand Rapids | Michigan | 49503 | — |
| Metro-Minnesota NCI Community Oncology Research Program | Minneapolis | Minnesota | 55416 | — |
| Mayo Clinic, Rochester, MN | Rochester | Minnesota | 55905 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Hackensack Medical Center | Hackensack | New Jersey | 07601 | — |
| The Valley Hospital, Okonite Research Center | Paramus | New Jersey | 07652 | — |
| New Mexico Cancer Care Alliance | Albuquerque | New Mexico | 87131 | — |
| Duke Cancer Institute | Durham | North Carolina | 27710 | — |
| First Health of the Carolinas Cancer Center | Pinehurst | North Carolina | 28374 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Legacy Good Samaritan Hospital | Portland | Oregon | 97210 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19106 | — |
| Lexington Medical Center | West Columbia | South Carolina | 29169 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37204 | — |
| MD Anderson | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute, University of Utah | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02947685, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 12, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02947685 live on ClinicalTrials.gov.